Tools   Select Another Resource Report Type

http://ki.se/meb/stanley-studien

This study will include 5000 individuals recruited from The National Quality Register for Bipolar Disorder (Bipol��R) and The National Patient Register (Patientregistret) from which subjects with two or more hospitalizations with bipolar disorder will be eligible for inclusion. Bipolar disorder (manodepressive illness) is an often devastating neuropsychiatric disorder associated with considerable morbidity, mortality, human suffering, and societal costs. Genetic epidemiological studies provide indirect evidence of the importance of inheritance as bipolar disorder is clearly familial. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 915 (June 2010)

Proper citation: KI Biobank - STANLEY (RRID:SCR_005922) Copy   

•   Source: SciCrunch Registry

http://ki.se/meb/star

Large, ongoing, multifactorial study based on nation-wide ascertainment of patients with schizophrenia and bipolar disorder through the Swedish Twin Registry to include both neuroimaging data, neurocognitive function, molecular genetic data and early adverse environmental factors in the same model in a genetic sensitive design. Swedish schizophrenia research will benefit from this large study database of in total 240 affected and healthy twin pairs collected over a 5 year period. The specific aims are: * To elucidate neural endophenotypes for schizophrenia and bipolar disorder and to clarify the extent of overlap in these features between the two syndromes. * To investigate candidate genes and genomic regions for linkage and association with neural endophenotypes for schizophrenia and bipolar disease. * To determine the contributions of adverse prenatal and perinatal conditions to neural changes associated with schizophrenia and bipolar disease. Types of samples * EDTA whole blood * DNA * RNA Number of sample donors: 251 (June 2010)

Proper citation: KI Biobank - STAR (RRID:SCR_005923) Copy   

•   Source: SciCrunch Registry

http://www.kreftregisteret.no/en/Research/Janus-Serum-Bank/

The Janus Serum Bank has blood samles from 317 000 Norwegians. The biobank is reserved for cancer research, and is internationally unique regarding size and number of cancer cases. The Janus Serum Bank is a population based biobank reserved for cancer research. The specimens are collected during the period from 1972-2004 and are stored at 25 degrees Celsius. The samples originate from 317 000 persons in Norway who have participated in health studies and also from blood donors in and around Oslo. Today, samples are only collected from earlier donors in the Janus Serum Bank who have developed cancer. The Bank is internationally unique regarding size and number of cancer cases. Annual linkage to the Cancer Registry shows that 52 500 donors are diagnosed with cancer as of December 31, 2009. The main goals of the biobank are to make the material available to cancer researchers over the whole world and deliver quality assured samples and data. The Janus Serum Bank is registered in the Biobank Register (Notification number 737)

Proper citation: Janus Serum Bank (RRID:SCR_005885) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/cns/mikael-landen-research-group

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 19,2022. The St G??ran Bipolar Study (SBP) is a prospective naturalistic study of patients suffering from bipolar disorder. Consenting patients are enrolled when diagnosed with any of Bipolar I, II, NOS disorder, cyclothymia, or schizoaffective disorder. At baseline, medical and social history is meticulously reviewed and the clinical diagnosis is established using a structured diagnostic instrument. Types of samples * EDTA whole blood * DNA * Plasma * Serum * Cerebrospinal fluid Number of sample donors: 371 (June 2010)

Proper citation: KI Biobank - SBP (RRID:SCR_005920) Copy   

•   Source: SciCrunch Registry

http://www.kcl.ac.uk/medicine/research/divisions/diiid/centres/pii/biobank/index.aspx

Centralized specimen archiving and molecular analysis facility that assists researchers wishing to undertake cohort-based projects in areas such HIV/AIDS, HCV infection or MRSA. Its aim is to make medical research easier, more efficient and faster to perform. The IDB collects valuable clinical samples from patients with infections who are attending their partner NHS-Trust clinics. Their core collections include blood samples from patients infected with human immunodeficiency virus (HIV), hepatitis B (HBV) & hepatitis C (HCV) viruses or methicillin resistant Staphylococcus aureus (MRSA). Blood samples are separated so that patients������?? DNA, plasmas (cell-free blood) and lymphocytes (white blood cells) can be frozen into a comprehensive library. Medical researchers can access complete sets of samples to answer important clinical questions, if their research project is approved by the IDB''s Management Committee. For this reason they are actively recruiting ''medically interesting'' patients who are infected with HIV, for example: those who remain well ������?? despite being infected for many years; others who are exposed to HIV but remain uninfected; others who develop AIDS very quickly; and, those who are in the process of sero-converting.

Proper citation: Kings College London Infectious Diseases BioBank (RRID:SCR_004827) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/broad

The study will collect 1,500 cases with schizophrenia and 1,500 well-matched controls ascertained via high-quality Swedish national hospitalization and population registries. Both cases and controls will be population-based and of Scandinavian ancestry. Types of samples * EDTA whole blood * DNA Number of donors: 10 820 (June 2010)

Proper citation: KI Biobank - BROAD (RRID:SCR_005916) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/twingene-and-genomeeutwin

In collaboration with GenomeEUtwin, the TwinGene project investigates the importance of quantitative trait loci and environmental factors for cardiovascular disease. It is well known that genetic factors are of considerable importance for some familial lipid syndromes and that Type A Behavior pattern and increased lipid levels infer increased risk for cardiovascular disease. It is furthermore known that genetic factors are of importance levels of blood lipid biomarkers. The interplay of genetic and environmental effects for these risk factors in a normal population is less well understood and virtually unknown for the elderly. In the TwinGene project twins born before 1958 are contacted to participate. Health and medication data are collected from self-reported questionnaires, and blood sampling material is mailed to the subject who then contacts a local health care center for blood sampling and a health check-up. In the simple health check-up, height, weight, circumference of waist and hip, and blood pressure are measured. Blood is sampled for DNA extraction, serum collection and clinical chemistry tests of C-reactive protein, total cholesterol, triglycerides, HDL and LDL cholesterol, apolipo��protein A1 and B, glucose and HbA1C. The TwinGene cohort contains more than 10000 of the expected final number of 16000 individuals. Molecular genetic techniques are being used to identify Quantitative Trait Loci (QTLs) for cardiovascular disease and biomarkers in the TwinGene participants. Genome-wide linkage and association studies are ongoing. DZ twins have been genome-scanned with 1000 STS markers and a subset of 300 MZ twins have been genome-scanned with Illumina 317K SNP platform. Association of positional candidate SNPs arising from these genomscans are planned. The TwinGene project is associated with the large European collaboration denoted GenomEUtwin (www.genomeutwin.org, see below) which since 2002 has aimed at gathering genetic data on twins in Europe and setting up the infrastructure needed to enable pooling of data and joint analyses. It has been the funding source for obtaining the genome scan data. Types of samples: * EDTA whole blood * DNA * Serum Number of sample donors: 12 044 (sample collection completed)

Proper citation: KI Biobank - TwinGene (RRID:SCR_006006) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29328&a=30572&l=en

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016.

Proper citation: KI Biobank - NOAK (RRID:SCR_006008) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=103615&l=en

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. The SALTY study will contact approximately 25 000 twins born 1943 - 1958. One of the main purposes with the study is to continue to build up the Swedish Twin Biobank which was established by the Twin Gene project.

Proper citation: KI Biobank - SALTY (RRID:SCR_006003) Copy   

•   Source: SciCrunch Registry

http://www.cryolife.com

A biological medical device company that focuses on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular for patients of all ages. The Company''s research and development efforts are focused on Protein Hydrogel Technologies, such as BioFoam Surgical Matrix for parenchymal organ sealing. The Company is also investigating additional applications for its SynerGraft decellularization technology. CryoLife provides surgeons with multiple tissue options for cardiovascular reconstruction. CryoLife preserved allografts have helped save the lives and limbs of patients for 20 years. CryoLife''s tissue, along with BioGlue and BioFoam offer a wide range of Life Restoring Technologies for cardiac and vascular surgeons. CryoLife provides innovative products that will benefit patients around the world by working with other pioneering companies and by continuous investment in research and development.

Proper citation: CryoLife, Inc. (RRID:SCR_005037) Copy   

•   Source: SciCrunch Registry

http://ki.se/forskning/kol-vaxande-epidemi-i-rokningens-spar

Aims to explore heritability for clinically confirmed chronic obstructive lung disease (COPD), estimate the heritability for lung function and investigate interactions between smoking and genes including the genetic effect on smoking habits. Study participants have been recruited from the Swedish Twin Registry. Types of samples * EDTA whole blood * DNA * Plasma * Serum Number of sample donors: 386 (sample collection completed)

Proper citation: KI Biobank - KOL (RRID:SCR_005782) Copy   

•   Source: SciCrunch Registry

http://www.rmtb.org/

The Rocky Mountain Tissue Bank is a Colorado, 501c3 non-profit corporation, established in 1980. It is governed by a Board of Directors and is an independent tissue processing facility with no affiliation with any other tissue bank. It develops and produces irradiated allogenic cancellous bone and marrow for human transplantation. This product stimulates bone regeneration in patients with bone loss due to trauma, disease, or genetic malformation and provides a foundation for dental implants. The primary distribution network is through Periodontists, and Oral Surgeons and clinicians specializing in implant dentistry.

Proper citation: Rocky Mountain Tissue Bank (RRID:SCR_004847) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/satsa-the-swedish-adoptiontwin-study-of-aging

Longitudinal twin study to understand individual differences in aging with corresponding data and biological samples. The twin design and the inclusion of twins reared apart makes it possible to study the importance of genetic and environmental factors that may underlie differing aging outcomes. Further, the broad spectrum of biological, psychological, and social domains assessed across the life span makes it possible to study patterns of change within and across domains and how these predict health and diseases of aging. The study is comprised of several longitudinal components including, a comprehensive questionnaire that was sent to all twins in the Swedish Twin Registry who were separated at an early age and reared apart and a control sample of twins reared together. The questionnaires include items concerning rearing, family, adult, and working environment, health status, health related behaviors (e.g. alcohol, tobacco, and dietary habits) as well as relationships, and personality measures. The questionnaires were sent again at 3 year intervals in 1987, 1990, 1993 and after a break again in 2004, 2007, and 2010. Thus far more than 2,000 twins have responded to at least one of the seven questionnaire assessments conducted between 1984 and 2010. Additionally there is information about midlife life style factors from the Swedish Twin Registry that were collected about twenty years before SATSA started. In the second component a subsample of 861 individuals have participated in at least one wave of in-person testing (IPT). The first IPT started in 1986 and since then eight IPTs have been collected and the last wave will be collected during 2012-2013. The IPT includes a health examination, structured interviews, tests of functional capacity, and memory and thinking abilities. To date, over 76% of the sample has participated in 3 or more measurement waves. At IPT9 a third component was added to SATSA, a measure of day-to-day fluctuations in memory and thinking abilities, and emotions. Information about social interactions is also collected. After the visit by the research nurses the twins fill out the day-to-day booklet during the next five days. This procedure will be repeated in IPT10. This will add information about small and short-term changes and more changes are supposed to indicate the beginning of poor health. Data from SATSA can be used to study various aspects of aging. For example, the relative importance of genetic and environmental factors for individual differences in aging especially in cognitive and physical domains has been studied. A further main focus is to study changes within and across domains and which genetic and life style factors predict these changes. Given the wide spectrum of data from measured genes to social relationships collected over more than two decades they dare to say that SATSA is a unique study, with the possibility to answer many questions within gerontology and geriatrics. Types of samples * Serum * DNA Number of sample donors: 674 (June 2010)

Proper citation: KI Biobank - SATSA (RRID:SCR_005966) Copy   

•   Source: SciCrunch Registry

http://pathology.wustl.edu/research/tissue.php

The Tissue Procurement Core Facility and Tumor Bank is a collaborative effort between the Siteman Cancer Center and the Department of Pathology and Immunology. This shared resource facility provides the resources, infrastructure, and technologies for biospecimen-based translational pathology research. Services include: Tissue Procurement, Processing, and Storage; Archival Frozen Tissue Bank; and Laser Capture Microdissection. * Tissue Procurement, Processing, and Storage: For investigators initiating new protocols that involve biospecimen collection (e.g. solid tissues, blood, bone marrow), the Core can provide model consent forms and personnel to collect specimens through the Division of Surgical Pathology and other clinical sites on campus. Solid tissues are usually snap frozen in the surgical pathology suite, although investigators may request alternate preservation methods. Blood specimens are generally processed to frozen serum aliquots and peripheral leukocyte cell pellets. Other specimens (e.g. lymph node needle aspirations) that may be obtained in a variety of other patient care areas can be collected and processed immediately by a staff member who is on call at all times to receive specimens. * Archival Frozen Tissue Bank: For investigators desiring immediate access to material for molecular and histological studies, an archive of over 18,000 frozen human biospecimens is available. Specimens include solid tumors, patient-matched non-malignant tissue, serum, and peripheral blood leukocytes. Each specimen is accompanied with basic patient demographic information and pathology diagnostic data. Generally, each frozen tissue specimen is reviewed to confirm that the specimen is representative of the written pathology diagnosis. Investigators may request frozen tissue sections for immunohistochemical analysis, genomic DNA, protein extracts, or cellular RNA derived from any specimen in the archive. * RNA Assessment: Cellular RNA prepared by the Core from banked specimens or any other RNA submitted by investigators can be qualitatively assessed by Agilent Bioanalyzer capillary microelectrophoresis and quantified by fiberoptic spectrophotometry, prior to use for downstream applications such as microarray or qRT-PCR analysis. * Laser Capture Microdissection: Pure cell populations are often needed for clonality, loss of heterozygosity (LOH), gene mutation, and mRNA expression analysis studies. The Core''s Pixcell II Laser Capture Microdissection (LCM) instrument can be used to dissect pure populations of cells from heterogeneous tissue sections. The instrument greatly enhances the speed and ease of dissection as compared to traditional manual methods. The instrument is available for use to investigators who wish to microdissect cells from either specimens stored in the Tissue Procurement Core or their own sets of collected tissue specimens.

Proper citation: Washington University Tissue Bank (RRID:SCR_004876) Copy   

•   Source: SciCrunch Registry

http://www.tmf-ev.de/BiobankenRegisterEN/Registry.aspx

German biobank registry containing names, addresses of the contact persons, web links and basic information of the biobanks. The Registry is available in German and English and is organized by content and by region. The goal is to create public awareness and understanding of the objectives and functions of biobanks, and to arrange collaborations between scientists. The registry cooperates with the European initiative Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Currently the first phase is implemented as an open access registry. A further expansion is planned with the possibility of online data entry and correction. The German Biobank Registry should help scientists and researchers, but also the interested public as an information gateway to serve. The functions of the registry are: * providing a publicly available registry of the medically relevant biobanks in Germany * improving the national and international visibility of German biobanks; * provision of partners for cooperation; * networking among biobanks; * promoting the exchange of information and of samples between research groups and institutions (hospitals, research institutes and pharmaceutical and biotech companies) operating biobanks; * improved use of existing resources; * promotion of transparency and understanding of the objectives and functions of biobanks in the general public; * Establishing a community to develop common solutions for legal and regulatory issues and thus avoiding redundant expenses for the individual researcher; * provide a planning basis for selective and efficient investments in new biobanks and the expansion of the existing infrastructure. The TMF is cooperating with the European BBMRI project to improve the biobank infrastructure in Europe. Data collection for the national registry is consistent with the survey of BBMRI project. You have to sample the data of your biobank only once and your biobank will be visible nationally and internationally. On the last page of the questionnaire you can give your consent for the use and publication of data for both projects (TMF and BBMRI) specifically. If you participate in the survey that has been harmonized for use throughout Europe by the BBMRI your biobank will be presented to the scientific community, potential partners for cooperations, funding organizations and sponsors. Furthermore, the survey provides an overview of the existing biobank infrastructure in Germany, and by this supports plans to ensure the sustainability and international competitiveness of German biobanks and the necessity of further financial support.

Proper citation: German Biobank Registry (RRID:SCR_004991) Copy   

•   Source: SciCrunch Registry

https://www.davincieuropeanbiobank.org/

BioBank that collects, stores, processes and distributes biospecimens and the associated data. The biospecimens are human and non-human genetic materials, proteins, cells, tissues and biofluids. The data are the biological information associated to the samples and, in the case of human samples, the clinical information pertaining to the donor. The da Vinci European BioBank (daVEB) is a multicenter biobank with a centralized IT infrastructure and a main repository located at the Polo Scientifico (Scientific Campus of the University of Florence) in Sesto Fiorentino (Florence, Italy). Hosted by the Magnetic Resonance Center (CERM), an expert center on protein structure and metabolomics, daVEB's aim is to host as rich as possible biological human sample collections, stored accordingly to EU guidelines, in order to offer a powerful tool in the study of complex diseases. At the end of July 2011, the da Vinci European BioBank of the Pharmacogenomics FiorGen Onlus Foundation has been audited and got the quality certification according to UNI EN ISO 9001:2008 for Collection, storage and distribution of biological samples and the associated data for scientific research. Besides the samples stored at da Vinci European BioBank in Sesto Fiorentino (Florence), the daVEB is also the administrative biobank for research sample collections that are stored in the delocalized repositories. All the sample collections must be registered in the biobank: * sample collections taken within the regular health care * samples taken from healthy individuals or other persons out of the regular health care * samples that have been taken in hospitals within research protocols on specific pathologies all transferred to daVEB endowed with a transfer agreement signed by the donor. The Research Units actually afferent to daVEB are delocalized in the Florence, Prato, Pisa and Siena provinces. Delocalized repositories are under construction in Tuscany.

Proper citation: da Vinci European Biobank (RRID:SCR_004908) Copy   

•   Source: SciCrunch Registry

http://godot.urol.uic.edu/andrology/index.php

The University Andrology Laboratory provides physicians and their patients with all forms of male infertility testing, as well as operating a Patient Sperm Banking Program. This full-service facility is dedicated to the diagnosis and treatment of the infertile male using the highest standard of quality of care. Patients can either visit the main laboratory facility on the University of Illinois at Chicago Medical Center campus or visit our satellite laboratory on North Michigan Avenue. Now available through the University Andrology Laboratory is the OverNiteMale Program. The OverNiteMale Program is particularly convenient for patients who are unable to make a personal visit to one of our laboratories to produce a sample. Patients can now produce a sample in the privacy of their own home from any location in the U.S.A. and send it via Federal Express directly to our laboratory. In-patients can also take advantage of the OverNiteMaleTM Program during their hospital stay. The University Andrology Laboratory was originally introduced at Michael Reese Hospital in Chicago in 1982 and relocated in 1996 to the University of Illinois at Chicago Medical Center, Department of Urology. The laboratory meets the highest standard of quality control and quality assurance. The operation of the University Andrology Laboratory has been under the direction of Gail S. Prins, Ph.D., HCLD, from its inception to the present.

Proper citation: University Andrology Laboratory (RRID:SCR_004901) Copy   

•   Source: SciCrunch Registry

http://www.cancerbiobank.org/

CCPRB (Cancer Control using Population-based Registries and Biobanks) is a Network of Excellence project within the sixth framework programme of the European Union. It is aiming at improved control of cancer by facilitating research linking biobanks and cancer registries. The project involves a systematic quality assurance and continuous development of standards and norms for human sample biobanks in Europe, as well as development of improved integrity-protection standards in the handling of sensitive information in connection with biobank-based research. The samples in the biobanks will be used in large-scale cancer research searching for genetic and infectious causes to cancer, in particular in the areas of breast and colorectal cancer and childhood leukemia. Project objectives: * Provide the study base for uniquely large population-based prospective studies on cancer * Define and implement a generally applicable European Quality Standard for Biobanking that will include improved data and specimen standardization, acquisition and analysis, reliable and standardized statistical analysis as well as improved management and co-ordination of European biobanks. * Define and promote the implementation of integrity-proof methods for biobank-based research involving well defined and secure third party code-keeping systems. * Enable large-scale, population-based research on: ** evaluation of cancer treatment and role of molecular markers in treatment selection ** use over-generation registry linkages applied to large biobank cohorts to identify and evaluate genetic predisposition associated with increased cancer risk as well as interactions with common environmental exposures. ** use over-generation registry linkages applied to large biobank cohorts to explore and evaluate intrauterine exposures associated with increased cancer risk ** exploit the power of large population cohorts for design of optimal strategies for cancer prevention and its evaluation. * Establish a Europe-wide network for spreading the awareness of i) the data, samples and knowledge generated European biobank-based research ii) possibilities for future biobank-based research and iii) the best practice quality standards for biobank-based research.

Proper citation: Cancer Control using Population-based Registries and Biobanks (RRID:SCR_004902) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/USIDNET/?SsId=15

The USIDNET DNA and Cell Repository has been established as part of an NIH-funded program - the US Immunodeficiency Network - to provide a resource of DNA and functional lymphoid cells obtained from patients with various primary immunodeficiency diseases. These uncommon disorders include patients with defects in T cell, B cell and/or granulocyte function as well as patients with abnormalities in antibodies / immunoglobulins, complement and other host defense mechanisms. All samples in this Repository have been de-identified to protect the privacy of the individual donors. The USIDNET also operates a Patient Data Registry in addition to this Repository and certain clinical data relating to a specific sample may be available through the Registry for some of the patient samples in the Repository collection. Materials in the collection are being made available at modest cost to qualified investigators in academic and commercial organizations in an effort to stimulate research to increase understanding of these orphan diseases and to promote development of new treatments. Requestors are required to complete a Statement of Research Intent briefly describing their proposed use of materials obtained from the Repository and must sign an Assurance agreeing to conditions established by USIDNET for distribution of samples from its collection. Requestors wishing to obtain additional clinical data specific to individual samples in the Repository collection must make a separate application for that information to the Registry (see www.usidnet.org) Physicians or Patients wishing to submit cell samples for the Repository collection should first contact Coriell to arrange for the Repository to send them the correct sample collection tubes as well as prepaid mailers for returning the collected sample(s) to Coriell. Separate collection and shipping procedures may be involved depending on how many samples are to be shipped at one time and whether the shipment will involve freshly obtained blood or already established cell lines.

Proper citation: USIDNET DNA and Cell Repository (RRID:SCR_004661) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=23686&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. The original aim of this study was to increase our understanding of the etiology of malignant lymphomas, especially in view of the increasing trend in incidence. Malignant lymphoma (including non-Hodgkin lymphoma, NHL, Hodgkin lymphoma, HL, and chronic lymphocytic leukemia, CLL) constitute a heterogeneous group of malignancies with regard to histology, molecular characteristics and clinical course. Etiological factors may also vary by lymphoma subtype. The incidence of NHL, the most common lymphoma group, has increased dramatically during the past decades in Sweden and in many other Western countries. The reasons for this increase as well as for the majority of all new cases is not well understood. Well established risk factors for lymphoma overall include hereditary and acquired disorders of strong immune dysfunction such as HIV/AIDS and organ transplantation, but they explain few new cases in the population. Approach: Population-based case-control study in Sweden and Denmark. The study includes in total 3740 patients and 3187 controls in both countries recruited during the period October 1999 to October 2002. Through a rapid case ascertainment system, the cases were identified shortly after diagnosis. The controls were randomly selected from national population registers and frequency-matched to the expected number of cases by sex and age group. Both cases and controls were interviewed by telephone based on a standardized questionnaire to obtain detailed information on potential risk factors for lymphoma such as medical history including infectious diseases, drug use and blood transfusions, socio-economic factors and life-style. Blood samples were also collected and stored as serum, plasma, DNA and live lymphocytes. In addition, written questionnaires about dietary habits or work exposures were sent out in Sweden. Tumor material from the cases was re-examined and uniformly classified according to the REAL classification. Status The data collection ended in 2002 and data analysis has been ongoing since then. We have primarily analyzed a range of environmental factors in relation risk of malignant lymphoma subgroups including sun exposure, body mass index, family history of hematopoietic cancer, allergy, autoimmune disorders and mononucleosis. We have also assessed specific genetic determinants in a subgroups of patients with follicular lymphoma and controls. Study results have so far been presented in 14 publications in peer-reviewed journals. In addition to new analyses on other environmental factors, we now also work to understand genetic susceptibility and gene-environmental interaction and risk of lymphoma. Also, prognostic studies have been initiated in collaboration with other research groups with regard to in CLL, HL and T-cell lymphoma.

Proper citation: SCALE - Scandinavian lymphoma etiology (RRID:SCR_006041) Copy   

•   Source: SciCrunch Registry